🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Neurofibroma

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas NCT05331105Phase 21 site📍 Shanghai Shanghai Kechow Pharma, Inc. · Tests: HL-085 Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas NCT07407803Phase 329 sites📍 Hefei📍 Beijing📍 Beijing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: TQ-B3234 capsules, TQ-B3234 placebo Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas NCT05253131Phase 21 site📍 Birmingham University of Alabama at Birmingham · Tests: Selumetinib + ZEN-3694 ± Durvalumab Glioma Developmental and HyperActive Ras Tumor (DHART) Board NCT05489783n/a7 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 NCT07102394Phase 11 site📍 Baltimore Johns Hopkins University · Tests: Imlygic Mirdametinib in Patients With Advanced NF1-mutant Melanoma NCT07237100Phase 21 site📍 San Francisco Kevin Kim, MD · Tests: Mirdametinib Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas NCT06502171Phase 18 sites📍 Birmingham📍 Los Angeles📍 Washington D.C. Girish Dhall, MD · Tests: Cabozantinib Oral Tablet, Selumetinib Oral Capsule A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1) NCT06507748NA2 sites📍 Washington D.C.📍 Bethesda National Cancer Institute (NCI) · Tests: AlgometRx Nociometer(R) A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 NCT06541847Phase 214 sites📍 Birmingham📍 Los Angeles📍 Palo Alto Healx Limited · Tests: HLX-1502 GROWing Up With Rare GENEtic Syndromes NCT04463316n/a1 site📍 Rotterdam dr. Laura C. G. de Graaff-Herder · Tests: Retrospective file studies Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN) NCT07888517n/a26 sites📍 Beijing📍 Changchun📍 Changsha AstraZeneca FARD (RaDiCo Cohort) (RaDiCo-FARD) NCT05954416n/a15 sites📍 Bobigny📍 Bordeaux📍 Bordeaux Institut National de la Santé Et de la Recherche Médicale, … Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors NCT03141021n/a13 sites📍 Tampa📍 Baltimore📍 Bethesda Washington University School of Medicine RASopathy Biorepository NCT04395495n/a1 site📍 Cincinnati Children's Hospital Medical Center, Cincinnati Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion NCT05245500Phase 125 sites📍 Phoenix📍 Lone Tree📍 Jacksonville Bristol-Myers Squibb · Tests: MRTX1719 SPEARHEAD-3 Pediatric Study NCT05642455Phase 1, Phase 210 sites📍 Palo Alto📍 Bethesda📍 Boston USWM CT, LLC · Tests: Afamitresgene autoleucel Familial Investigations of Childhood Cancer Predisposition NCT03050268n/a1 site📍 Memphis St. Jude Children's Research Hospital Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) NCT06222203n/a1 site📍 Bethesda National Cancer Institute (NCI) MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam Real-World Treatment Study of Koselugo (Selumetinib) NCT06360406n/a12 sites📍 Busan📍 Chungcheongbuk-do📍 Daejeon AstraZeneca A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors NCT05985161Phase 216 sites📍 Los Angeles📍 Palo Alto📍 Washington D.C. Memorial Sloan Kettering Cancer Center · Tests: Selinexor A Study of DEG6498 in Participants With Solid Tumors NCT07244835Phase 13 sites📍 Beijing📍 Beijing📍 Guangzhou Degron Therapeutics Co. · Tests: DEG6498 MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma NCT06277154Phase 21 site📍 Guangzhou HRYZ Biotech Co. · Tests: MASCT-I, Doxorubicin, Ifosfamide Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy NCT07233408NA1 site📍 Boston Massachusetts General Hospital · Tests: NF1 Educational Videos, Peer Navigator, Letters about NF1 Care Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study NCT06880991n/a1 site📍 Bethesda National Cancer Institute (NCI) · Tests: Arm 1 Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial NCT05361811NA1 site📍 Bethesda National Cancer Institute (NCI) · Tests: Waitlist, ACT Intervention Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors NCT05732831Phase 1, Phase 226 sites📍 Palo Alto📍 Grand Junction📍 Lake Mary Tango Therapeutics, Inc. · Tests: TNG462, Pembrolizumab Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15 NCT03893643n/a1 site📍 Nice Centre Hospitalier Universitaire de Nice · Tests: no intervention IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) NCT06849986Phase 21 site📍 Shanghai Fudan University · Tests: Tislelizumab+liposomal doxorubicin+ifosfamide DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins NCT07298083n/a1 site📍 Houston M.D. Anderson Cancer Center
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy